Yulia Komleva

Dr. Yulia Komleva

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2015 in The International Journal of Biochemistry & Cell Biology
Verified
Journal Article
Closed access
ASAlla Salmina
Alla Salmina
NKNatalia V. Kuvacheva
Natalia V. Kuvacheva
AMAndrey Morgun
Andrey Morgun
YKYulia Komleva
Yulia Komleva
Elena PozhilenkovaElena Pozhilenkova
Elena Pozhilenkova
LPLyudmila L. Petrova
Lyudmila L. Petrova

Verified
Journal Article
Open access
PDF file
ASAlla Salmina
Alla Salmina
EKEkaterina V. Kharitonova
Ekaterina V. Kharitonova
YGYana V. Gorina
Yana V. Gorina
ETElena A. Teplyashina
Elena A. Teplyashina
NMNatalia A. Malinovskaya
Natalia A. Malinovskaya
YKYulia Komleva
Yulia Komleva
Pathophysiology of chronic neurodegeneration is mainly based on complex mechanisms related to aberrant signal transduction, excitation/inhibition imbalance, excitotoxicity, synaptic dysfunction, oxidative stress, proteotoxicity and protein misfolding, local insulin resistance and metabolic dysfunction, excessive cell death, development of glia-supported neuroinflammation, and failure of neurogenesis. These mechanisms tightly associate with dramatic alterations in the structure and activity of the neurovascular unit (NVU) and the blood–brain barrier (BBB). NVU is an ensemble of brain cells (brain microvessel endothelial cells (BMECs), astrocytes, pericytes, neurons, and microglia) serving for the adjustment of cell-to-cell interactions, metabolic coupling, local microcirculation, and neuronal excitability to the actual needs of the brain. The part of the NVU known as a BBB controls selective access of endogenous and exogenous molecules to the brain tissue and efflux of metabolites to the blood, thereby providing maintenance of brain chemical homeostasis critical for efficient signal transduction and brain plasticity. In Alzheimer’s disease, mitochondria are the target organelles for amyloid-induced neurodegeneration and alterations in NVU metabolic coupling or BBB breakdown. In this review we discuss understandings on mitochondria-driven NVU and BBB dysfunction, and how it might be studied in current and prospective NVU/BBB in vitro models for finding new approaches for the efficient pharmacotherapy of Alzheimer’s disease.

26 August 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
ASAlla Salmina
Alla Salmina
YGYana V. Gorina
Yana V. Gorina
YKYulia Komleva
Yulia Komleva
YPYulia A. Panina
Yulia A. Panina
NMNatalia A. Malinovskaya
Natalia A. Malinovskaya
OLOlga Lopatina
Olga Lopatina
Early life stress (ELS) causes long-lasting changes in brain plasticity induced by the exposure to stress factors acting prenatally or in the early postnatal ontogenesis due to hyperactivation of hypothalamic-pituitary-adrenal axis and sympathetic nervous system, development of neuroinflammation, aberrant neurogenesis and angiogenesis, and significant alterations in brain metabolism that lead to neurological deficits and higher susceptibility to development of brain disorders later in the life. As a key component of complex pathogenesis, ELS-mediated changes in brain metabolism associate with development of mitochondrial dysfunction, loss of appropriate mitochondria quality control and mitochondrial dynamics, deregulation of metabolic reprogramming. These mechanisms are particularly critical for maintaining the pool and development of brain cells within neurogenic and angiogenic niches. In this review, we focus on brain mitochondria and energy metabolism related to tightly coupled neurogenic and angiogenic events in healthy and ELS-affected brain, and new opportunities to develop efficient therapeutic strategies aimed to restore brain metabolism and reduce ELS-induced impairments of brain plasticity.

1 February 2021 in Brain Research
Verified
Journal Article
Closed access
YKYulia Komleva
Yulia Komleva
OLOlga L. Lopatina
Olga L. Lopatina
IGIana V. Gorina
Iana V. Gorina
ASAnton N. Shuvaev
Anton N. Shuvaev
ACAnatoly Chernykh
Anatoly Chernykh
ASAlla B. Salmina
Alla B. Salmina

19 January 2025 in Cells
Verified
Journal Article
Open access
PDF file
PTPavel P. Tregub
Pavel P. Tregub
YKYulia Komleva
Yulia Komleva
MKMaria V. Kukla
Maria V. Kukla
AAAnton Averchuk
Anton Averchuk
AVAnna Sergeevna Vetchinova
Anna Sergeevna Vetchinova
ASAlla Salmina
Alla Salmina
Brain plasticity is at the basis of many cognitive functions, including learning and memory. It includes several mechanisms of synaptic and extrasynaptic changes, neurogenesis, and the formation and elimination of synapses. The plasticity of synaptic transmission involves the expression of immediate early genes (IEGs) that regulate neuronal activity, thereby supporting learning and memory. In addition, IEGs are involved in the regulation of brain cells’ metabolism, proliferation, and survival, in the establishment of multicellular ensembles, and, presumably, in cell competition in the tissue. In this review, we analyze the current understanding of the role of IEGs (c-Fos, c-Myc, Arg3.1/Arc) in controlling brain plasticity in physiological and pathological conditions, including brain aging and neurodegeneration. This work might inspire new gene therapy strategies targeting IEGs to regulate synaptic plasticity, and potentially prevent or mitigate neurodegenerative diseases.

6 December 2024 in Biomolecules
Verified
Journal Article
Open access
PDF file
NKNataliya A. Kolotyeva
Nataliya A. Kolotyeva
AGAlexander A. Groshkov
Alexander A. Groshkov
NRNataliya A. Rozanova
Nataliya A. Rozanova
ABArseniy K. Berdnikov
Arseniy K. Berdnikov
SNSvetlana V. Novikova
Svetlana V. Novikova
MPMikhail A. Piradov
Mikhail A. Piradov
NAD+ plays a pivotal role in energy metabolism and adaptation to external stimuli and stressful conditions. A significant reduction in intracellular NAD+ levels is associated with aging and contributes to the development of chronic cardiovascular, neurodegenerative, and metabolic diseases. It is of particular importance to maintain optimal levels of NAD+ in cells with high energy consumption, particularly in the brain. Maintaining the tissue level of NAD+ with pharmacological tools has the potential to slow down the aging process, to prevent the development of age-related diseases. This review covers key aspects of NAD+ metabolism in terms of brain metabolic plasticity, including NAD+ biosynthesis and degradation in different types of brain cells, as well as its contribution to the development of neurodegeneration and aging, and highlights up-to-date approaches to modulate NAD+ levels in brain cells.